Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $9.30

Pediatrix Medical Group, Inc. (NYSE:MD) has earned a consensus rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.30.

MD has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft raised Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price objective for the company in a report on Friday, June 7th. Jefferies Financial Group raised Pediatrix Medical Group from a “hold” rating to a “buy” rating and increased their price objective for the company from $8.00 to $14.00 in a report on Thursday. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial increased their price target on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, UBS Group increased their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th.

Insider Buying and Selling

In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now owns 175,347 shares of the company’s stock, valued at $1,767,497.76. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock valued at $701,889 over the last three months. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $31,000. Innealta Capital LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $33,000. Nisa Investment Advisors LLC increased its position in shares of Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after buying an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $72,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in shares of Pediatrix Medical Group in the second quarter valued at $81,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

Shares of Pediatrix Medical Group stock opened at $11.26 on Friday. The firm has a market capitalization of $966.90 million, a P/E ratio of -13.25, a P/E/G ratio of 1.64 and a beta of 1.56. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $13.01. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87. The firm’s 50 day moving average is $10.04 and its two-hundred day moving average is $8.88.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. The business had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The company’s revenue was up .7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.37 earnings per share. Research analysts forecast that Pediatrix Medical Group will post 1.19 EPS for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.